Industry news that matters to you.  Learn more

Paper Demonstrates New Top-Down Approach for Identifying Low Abundance Biomarkers

A recent article in Proteomics Clinical Applications demonstrates the validity of a new top-down proteomics approach to identifying low-abundance biomarkers in the one percent of serum/plasma proteins known as the deep proteome. Applying this methodology, French researchers identified a potential biomarker that might be used to track a patient’s recovery from a myocardial infarction (heart attack). Specifically, their goal was to develop indicators that would more accurately predict a complex process called “left ventricular remodeling” that occurs in response to heart damage and leads to heart failure.

Consortium Develops Algorithm from Blood-Based Alzheimer’s Biomarkers

In a study appearing in the newest issue of the Archives of Neurology, members of the Texas Alzheimer’s Research Consortium reported that they have identified protein biomarkers in the blood that can be used to distinguish between individuals with and without Alzheimer’s disease.

Study: PET Biomarker Gets Validation for Alzheimer’s Disease

18F-Flutemetamol performs similarly to the 11C-Pittsburgh compound B (11C-PIB) parent molecule within the same subjects and provides high test-retest replicability and potentially much wider accessibility for clinical and research use for Alzheimer’s disease, based on a study in the September issue of the Annals of Neurology.

Immunogenicity Testing Proves Invaluable

Immunogenicity is a measure of the immune response to a biotherapeutic drug. It is a very relevant issue affecting not only the use of therapeutic protein drugs such as mAbs but also peptides, enzymes, cytokines, growth factors, recombinant proteins, and other biological products.

Micropatch Detects Disease Biomarkers in Skin

Scientists in Australia have built a microneedle device capable of detecting disease-specific proteins directly from the skin.